Implantable Pulse Generator Market Report 2024

This Implantable Pulse Generator market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The implantable pulse generator market size has grown strongly in recent years. It will grow from $99.52 billion in 2023 to $107.09 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to several factors, the expansion of home healthcare facilities, increased adoption of neuromodulation for disease management, higher diagnosis rates, growing usage of medical devices, and increased patient awareness.

The implantable pulse generator market size is expected to see strong growth in the next few years. It will grow to $144.31 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The anticipated growth during the forecast period can be attributed to several factors, rising healthcare expenditure, patient preference for less invasive treatments, favorable reimbursement policies, expansion of application areas, and increased use of implants in various therapies. Key trends expected to influence this growth include the miniaturization of devices, improved battery life, development of wireless connectivity, smart implantable devices, and the integration of artificial intelligence and machine learning.

The increasing prevalence of neurological disorders is expected to drive the growth of the implantable pulse generator market. Neurological disorders affect the brain, spinal cord, and nervous system, impacting movement, sensation, and cognition. The rise in these disorders is linked to factors such as an aging population, lifestyle changes, environmental influences, and advancements in diagnostic techniques. Implantable pulse generators assist in managing neurological disorders by delivering targeted electrical impulses to modulate abnormal neural activity and alleviate symptoms. For example, as reported by the Parkinson Foundation in December 2022, the number of individuals with Parkinson's disease (PD) in the U.S. was 930,000 by 2020, with projections indicating it will reach 1.2 million by 2030. Thus, the growing incidence of neurological disorders is fueling the expansion of the implantable pulse generator market.

Companies in the implantable pulse generator market are focusing on developing advanced neuromodulation devices to improve treatment effectiveness, patient outcomes, and broaden the range of conditions treated. Neuromodulation devices alter nerve activity by delivering electrical or pharmaceutical agents to specific areas of the nervous system. For instance, in November 2022, CVRx Inc., a U.S.-based medical device company, introduced the Barostim NEO2 IPG, a new implantable pulse generator designed for patients undergoing therapy. The Barostim system uses neuromodulation to alleviate heart failure symptoms by delivering electrical pulses to the baroreceptors in the carotid artery, activating the body’s baroreflex and inducing an autonomic response in the heart. The goal is to restore balance to the autonomic nervous system and reduce heart failure symptoms.

In March 2021, Bioventus Inc., a U.S.-based medical device company, acquired Bioness Inc. for an undisclosed amount. This acquisition allows Bioventus to leverage Bioness's extensive range of medical devices and technologies, which support recovery for patients with conditions such as stroke, traumatic brain injury, and osteoarthritis. The portfolio includes specialized electrical stimulation devices and robotic systems critical for patient rehabilitation. Bioness Inc. is a U.S.-based company known for its electromedical devices.

Major companies operating in the implantable pulse generator market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Integer Holdings Corporation, Livanova plc, Inspire Medical Systems Inc., Nevro Corp, Impulse Dynamics Ltd., Valtronic Inc., NeuroPace Inc., SPR Therapeutics Inc., Stimwave LLC, SetPoint Medical, ReShape Lifesciences Inc., Synapse Biomedical Inc., Nuvectra Medical Inc., NeuroSigma Inc., Nalu Medical Inc., MainStay Medical International PLC, Dextronix Inc., BioControl Medical Inc.

North America was the largest region in the implantable pulse generator market in 2023. The regions covered in the implantable pulse generator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the implantable pulse generator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An implantable pulse generator (IPG) is a medical device used to deliver electrical impulses to specific nerves or muscles within the body. It is commonly employed in neuromodulation therapies to manage conditions such as chronic pain or movement disorders. The IPG is surgically implanted under the skin and can be programmed to adjust stimulation levels as required.

The primary types of implantable pulse generators include implantable cardiac pacemakers, implantable defibrillators, cochlear implants, implantable nerve stimulators (functional electrical stimulation or FES), implantable infusion pumps, and implantable active monitoring devices. Implantable cardiac pacemakers, for example, are devices placed in the chest to regulate abnormal heart rhythms by delivering electrical impulses to stimulate the heart. They come in rechargeable and non-rechargeable variants and are used for cardiovascular diseases, movement disorders, orthopedic conditions, and other health issues. End users of these devices include hospitals, ambulatory surgical centers, home care settings, and clinics.

The implantable pulse generator market research report is one of a series of new reports that provides Implantable pulse generator market statistics, including the implantable pulse generator industry's global market size, regional shares, competitors with an implantable pulse generator market share, detailed implantable pulse generator market segments, market trends and opportunities, and any further data you may need to thrive in the implantable pulse generator industry. This implantable pulse generator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The implantable pulse generator market consists of sales of neurostimulators, sacral nerve stimulators, and deep brain stimulation (DBS) systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.